Novo Nordisk's NovoSeven To Enter Clinic For Trauma Bleeding

A U.S. clinical trial for a trauma bleeding indication for Novo's recombinant Factor VIIa hemophilia treatment will begin within six months, the company says. FDA recently lifted a clinical hold based on European safety data.